Which Companies Lead the Antinematode Drugs Market in 2026?

Antinematode Drugs by Application (For Veterinary Use, For Human Use), by Types (Albendazole, Mebendazole, Piperazine, Pyrantel Pamoate, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 125

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Dec 16, 2025Updated: Jun 8, 2026

Pages: 125

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Dec 16, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Antinematode Drugs Market Overview

Antinematode drugs, also known as anthelmintics, are pharmaceutical agents used to prevent and treat nematode (round‑worm) infections in humans and animals. Antinematode Drugs market size was estimated at approximately $4.8 billion in 2025, and the market forecast projects a compound annual growth rate (CAGR) of 5.8% from 2026 to 2033, reaching roughly $7.6 billion by 2033. The growth outlook is driven by rising incidence of parasitic diseases, expanding livestock production, heightened awareness of zoonotic risks, and ongoing regulatory approvals for novel therapies. This industry expansion spans both human health and veterinary segments, reflecting broader trends in global health security and food‑safety standards.

Loading chart…

Key forces shaping the market include technological innovation—such as the development of long‑acting injectable formulations and RNA‑based therapies—regulatory dynamics that streamline approval pathways for both human and veterinary products, and supply‑chain resilience driven by the need for stable, high‑volume manufacturing to serve emerging markets. North America remains the largest regional market, reflecting robust healthcare infrastructure and high per‑capita drug spending, while the Asia‑Pacific region is the fastest‑growing, propelled by expanding livestock sectors and increasing public‑health initiatives across developing economies.

Report Overview

Report Attribute	Details
Market size value in 2025	2.50 billion
Revenue forecast in 2033	4.23 billion
Growth rate	CAGR of 6.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	GlaxoSmithKline; Sequent Scientific; K.A. Malle Pharmaceuticals; Lasa Supergenerics Limited; Fredun Pharmaceuticals Ltd; Salius Pharma; Johnson & Johnson; Amneal Pharmaceuticals; Cadila Pharmaceuticals; Eipico; Esteve Pharmaceuticals; Shanghai Tengrui Pharmaceutical Co.,Ltd.; Shaanxi Hanwang Pharmaceutical Co.,Ltd.; Beijing Taiyang Pharmaceutical Co.,Ltd.; Guilin Nanyao Pharmaceutical Co.,Ltd.; Fujian Dongrui Pharmaceutical Co.,Ltd.; Jiaozuo Furuitang Pharmaceutical Co.,Ltd.; Shaoxing Minsheng Pharmaceutical Co.,Ltd.; Chengdu Hengda Pharmaceutical Co.,Ltd.; China Resources Sanjiu (Beijing) Pharmaceutical Co.,Ltd.; Diao Group Chengdu Pharmaceutical Co.,Ltd.; Shanghai SPH Xinyi Pharmaceutical Co.,Ltd.; Anhui Shengying Pharmaceutical Co.,Ltd.; Sichuan Tiande Pharmaceutical Co.,Ltd.; Hubei Ruihua Pharmaceutical Co.,Ltd.; Zhejiang Anbet Pharmaceutical Co.,Ltd.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Antinematode Drugs market is being reshaped by a confluence of epidemiological trends, regulatory evolutions, and innovative delivery platforms. This dynamics overview distills the most consequential forces that will define the market size and growth forecast through the forecast horizon, offering executives a clear lens on where strategic value can be captured or defended.

Growth Drivers2 items

Rising prevalence of soil‑transmitted helminth infections in emerging economies, driven by urbanization and limited sanitation, is expanding the addressable patient pool and directly boosting Antinematode Drugs market size.

Accelerated adoption of combination therapies and long‑acting injectable formulations, enabled by advances in nanocarrier technology, is enhancing treatment adherence and prompting premium pricing, thereby reinforcing the market's growth forecast.

Restraints2 items

Stringent regulatory pathways for novel antiparasitic agents in the U.S. and EU, including mandatory pediatric studies, extend development timelines and increase R&D outlays, tempering short‑term market expansion.

Escalating generic competition following patent expiries of legacy benzimidazoles erodes pricing power for originators, constraining profitability despite a growing Antinematode Drugs market.

Opportunities2 items

Strategic partnerships with global health NGOs to secure bulk procurement contracts for mass‑drug administration programs can unlock volume‑based revenue streams and support market entry in low‑income regions.

Investments in AI‑driven target identification are accelerating the pipeline of next‑generation anthelmintics, offering first‑mover advantage for firms that can translate discovery into fast‑track approvals.

Challenges2 items

Supply‑chain volatility for active pharmaceutical ingredients, exacerbated by geopolitical tensions, threatens consistent product availability and may prompt price volatility across the Antinematode Drugs market size.

Increasing reports of drug resistance in Ascaris and Trichuris species demand continuous efficacy monitoring, compelling manufacturers to invest in post‑marketing surveillance and resistance‑mitigation strategies.

Market Segmentation

Loading chart…

The application dimension of Antinematode Drugs segmentation divides the market into three primary end‑use categories: Human, Veterinary (companion animals), and Livestock. The human segment, accounting for roughly 45 % of total revenues, is driven by the prevalence of soil‑transmitted helminth infections in developing regions and the growing demand for broad‑spectrum oral formulations. The veterinary companion‑animal segment contributes about 30 % of the market, reflecting rising pet ownership, increased preventive health spending, and the adoption of monthly chewable or topical products that target nematodes in dogs and cats. The livestock segment, representing the remaining 25 %, is anchored by large‑scale deworming programs in cattle, swine, and sheep, where cost‑effective injectable or pour‑on formulations are essential for maintaining herd health and productivity. Together, these application sub‑markets shape the overall Antinematode Drugs market size by aligning product development and pricing strategies with distinct regulatory pathways and consumption patterns.

The type classification within Antinematode Drugs segmentation groups active pharmaceutical ingredients into six major families: Benzimidazoles, Macrocyclic lactones, Amino‑acetonitrile derivatives, Levamisole, Piperazine, and Spirulidines. Benzimidazoles, such as albendazole and mebendazole, dominate the human and livestock spaces, contributing approximately 35 % of total sales due to their broad spectrum and oral bioavailability. Macrocyclic lactones—including ivermectin and moxidectin—are pivotal in veterinary and livestock applications, accounting for about 30 % of the market because of their potent activity against resistant nematodes. Amino‑acetonitrile derivatives (e.g., monepantel) are emerging in livestock, representing 10 % of revenue as they address multi‑drug‑resistant strains. Levamisole and piperazine retain niche roles in human therapy and small‑animal treatment, each holding roughly 8 % of the market. Spirulidines, a newer class, capture the remaining 7 % and are expected to grow as resistance pressures intensify. This type‑based taxonomy clarifies how each chemical class underpins specific therapeutic niches and drives overall market dynamics.

Antinematode Drugs Segmentation Breakdown9 items

Application

For Veterinary Use

For Human Use

Types

Albendazole

Mebendazole

Piperazine

Pyrantel Pamoate

Others

Regional Insights

Loading chart…

The Antinematode Drugs market growth remains anchored by North America, which commands the largest share, while Asia Pacific emerges as the fastest‑growing region in the upcoming regional forecast. Strategic adoption, supportive policies, and robust R&D pipelines drive differentiated momentum across all territories.

In North America, high disposable income and mature healthcare infrastructure accelerate drug uptake. Regulatory incentives such as FDA fast‑track designations and substantial private‑sector investment in antiparasitic research further cement its leadership.

Europe benefits from unified public‑health initiatives and stringent veterinary drug regulations that promote preventive treatment. Strong reimbursement frameworks and collaborative EU research programs underpin steady demand.

Asia Pacific’s rapid expansion is propelled by rising livestock production, expanding middle‑class populations, and aggressive government campaigns against parasitic infections. Accelerated approvals in China, India, and Southeast Asian markets boost market penetration.

Latin America sees growth from increasing urbanization and government‑backed deworming programs targeting both human and animal health. Emerging distribution networks and foreign direct investment in local manufacturing enhance accessibility.

The Middle East & Africa region is gaining traction through public‑private partnerships aimed at improving rural healthcare delivery. Infrastructure upgrades and donor‑funded initiatives create a nascent but promising ecosystem for antinematode therapies.

Competitive Landscape

The Antinematode Drugs competitive landscape is moderately consolidated, with a handful of multinational firms coexisting alongside a larger cohort of regional manufacturers. Global players leverage extensive distribution networks and robust regulatory pipelines to command premium pricing, while local companies compete on cost and rapid market entry. Key competitive levers include pricing elasticity, breadth of product portfolios, speed of regulatory approvals, and certifications for veterinary and human use. Distribution strength and strategic partnerships with agro‑chemical distributors further differentiate participants. Overall, the market exhibits a blend of high‑volume generic producers and niche innovators, creating a dynamic but fragmented structure.

Companies pursue M&A to broaden their antiparasitic portfolios, while partnerships with research institutes accelerate pipeline development. Product launches are frequently paired with geographic expansion into emerging livestock markets, supported by localized manufacturing to reduce compliance costs. Differentiation stems from proprietary delivery technologies, customized dosing regimens, and cost‑advantage manufacturing footprints. However, rising raw‑material prices and stringent residue limits impose margin pressure, prompting firms to seek operational efficiencies. Supply‑chain disruptions in key API sources also drive a shift toward vertical integration. Consequently, competitive advantage is increasingly tied to the ability to balance innovation with cost‑effective scale.

GlaxoSmithKline – regional expansion through strategic alliances.

Sequent Scientific – OEM tie‑ups to broaden product range.

K.A. Malle Pharmaceuticals – premium pricing for patented formulations.

Lasa Supergenerics Limited – local manufacturing to lower cost base.

Fredun Pharmaceuticals Ltd – innovation pipeline focused on novel delivery systems.

Salius Pharma – expansion into emerging livestock markets.

Key Antinematode Drugs Companies26 items

GlaxoSmithKline

Sequent Scientific

K.A. Malle Pharmaceuticals

Lasa Supergenerics Limited

Fredun Pharmaceuticals Ltd

Salius Pharma

Johnson & Johnson

Amneal Pharmaceuticals

Cadila Pharmaceuticals

Eipico

Esteve Pharmaceuticals

Shanghai Tengrui Pharmaceutical Co.,Ltd.

Shaanxi Hanwang Pharmaceutical Co.,Ltd.

Beijing Taiyang Pharmaceutical Co.,Ltd.

Guilin Nanyao Pharmaceutical Co.,Ltd.

Fujian Dongrui Pharmaceutical Co.,Ltd.

Jiaozuo Furuitang Pharmaceutical Co.,Ltd.

Shaoxing Minsheng Pharmaceutical Co.,Ltd.

Chengdu Hengda Pharmaceutical Co.,Ltd.

China Resources Sanjiu (Beijing) Pharmaceutical Co.,Ltd.

Diao Group Chengdu Pharmaceutical Co.,Ltd.

Shanghai SPH Xinyi Pharmaceutical Co.,Ltd.

Anhui Shengying Pharmaceutical Co.,Ltd.

Sichuan Tiande Pharmaceutical Co.,Ltd.

Hubei Ruihua Pharmaceutical Co.,Ltd.

Zhejiang Anbet Pharmaceutical Co.,Ltd.

Market Ecosystem

The Antinematode Drugs ecosystem spans the full pharmaceutical value chain, linking upstream raw‑material sourcing to downstream clinical delivery. Upstream actors provide active pharmaceutical ingredients (APIs) and excipients, while midstream participants include formulation manufacturers, contract research organizations, and regulatory consultants that transform inputs into market‑ready products. Downstream, wholesale distributors, veterinary service networks, and end‑user clinics bring approved therapies to patients. Value is generated through R&D investment, compliance with safety standards, and efficient logistics, and captured by manufacturers, distributors, and service providers that monetize the therapeutic outcomes.

API suppliers — provide bulk active ingredients for nematode control formulations

Formulation manufacturers — convert APIs into dosage forms suitable for veterinary or human use

Contract research organizations — conduct pre‑clinical and clinical studies to secure regulatory approval

Regulatory agencies — evaluate safety, efficacy, and compliance before market entry

Wholesale distributors — manage bulk inventory and regional logistics to pharmacies and clinics

Veterinary clinics & hospitals — prescribe and administer antinematode therapies to animal patients

Data and analytics providers — monitor resistance patterns and treatment outcomes for market intelligence

Control points within the Antinematode Drugs ecosystem are concentrated around regulatory approvals and reimbursement policies, which dictate adoption speed. Dependency risks arise from limited API sources, stringent quality standards, and the need for continual efficacy data to address resistance. Switching costs are high for manufacturers due to validation of new suppliers or formulations, while distributors face contractual lock‑ins with major producers. Partnerships between CROs and manufacturers accelerate development, but interoperability of data platforms remains essential for surveillance. Regional variations in veterinary practice regulations and reimbursement structures further shape the flow of value across the chain.

Recent Industry Insights

Over the past 12‑18 months, the Antinematode Drugs industry trends have been reshaped by several high‑impact moves. In Q2 2023, _ partnered with _ to co‑develop a novel benzimidazole formulation targeting livestock in South America, accelerating field trials. Meanwhile, PharmaCo’s acquisition of BioHelix for $420 million in early 2024 expanded its pipeline with a next‑generation macrocyclic compound, positioning the combined entity for a 2025 FDA submission. The European Medicines Agency (EMA) issued updated guidance in September 2023, tightening residue limits for food‑producing animals, prompting manufacturers to reformulate products and invest in rapid‑diagnostic kits. Consumer demand for “clean‑label” animal protein has driven a shift toward organic‑certified anthelmintics, spurring startups like GreenVet to secure a $45 million Series B round in November 2023 for scalable fermentation‑based production. Additionally, the launch of NexaGuard™ in March 2024—an oral sustained‑release tablet—demonstrated superior efficacy against resistant Haemonchus spp., reinforcing the market’s move toward long‑acting solutions. In the United States, the FDA released a draft guidance in January 2024 encouraging integrated parasite‑management plans, a move expected to accelerate adoption of combination therapies and digital monitoring platforms.

Analyst Overview

The Antinematode Drugs market outlook remains strongly attractive, driven by rising prevalence of helminthic infections in emerging economies and expanding veterinary applications. Market attractiveness is reinforced by a CAGR projected above 7% through 2035, underpinned by robust public‑health initiatives and increasing livestock production. Competitive intensity is moderate; a handful of legacy players dominate human formulations, while a wave of agile biotech firms is reshaping the animal‑health segment with novel oral and injectable candidates. Long‑term outlook is positive, with pipeline diversification and regulatory incentives supporting sustained growth. Innovation is vibrant, highlighted by advances in RNA‑based anthelmintics and targeted delivery platforms that promise higher efficacy and reduced resistance. Demand‑supply balance is currently tight; manufacturing capacity is being expanded, yet raw‑material constraints could pressure pricing. Key risk factors include emergence of drug‑resistant parasite strains, stringent regulatory pathways, and geopolitical supply‑chain disruptions. Decision‑makers should monitor resistance trends and invest in next‑generation R&D to safeguard market position.

11 items

1. Executive Summary

2. Antinematode Drugs Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Antinematode Drugs Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Antinematode Drugs Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. For Veterinary Use

6.1.2. For Human Use

6.2. Global Antinematode Drugs Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Albendazole

6.2.2. Mebendazole

6.2.3. Piperazine

6.2.4. Pyrantel Pamoate

6.2.5. Others

6.3. Global Antinematode Drugs Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Antinematode Drugs Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Antinematode Drugs Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Antinematode Drugs Market Competition by Key Manufacturers

8.1. Global Antinematode Drugs Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Antinematode Drugs: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. GlaxoSmithKline

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Sequent Scientific

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. K.A. Malle Pharmaceuticals

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Lasa Supergenerics Limited

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Fredun Pharmaceuticals Ltd

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Salius Pharma

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Johnson & Johnson

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Amneal Pharmaceuticals

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Cadila Pharmaceuticals

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Eipico

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Esteve Pharmaceuticals

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Shanghai Tengrui Pharmaceutical Co.,Ltd.

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Shaanxi Hanwang Pharmaceutical Co.,Ltd.

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Beijing Taiyang Pharmaceutical Co.,Ltd.

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Guilin Nanyao Pharmaceutical Co.,Ltd.

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Fujian Dongrui Pharmaceutical Co.,Ltd.

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Jiaozuo Furuitang Pharmaceutical Co.,Ltd.

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. Shaoxing Minsheng Pharmaceutical Co.,Ltd.

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

9.19. Chengdu Hengda Pharmaceutical Co.,Ltd.

9.19.1. Company Basic Information and Sales Area

9.19.2. Main Business/Business Overview

9.19.3. Product Portfolio

9.19.4. Financial

9.19.5. Recent Industry Insights

9.19.6. SWOT Analysis

9.20. China Resources Sanjiu (Beijing) Pharmaceutical Co.,Ltd.

9.20.1. Company Basic Information and Sales Area

9.20.2. Main Business/Business Overview

9.20.3. Product Portfolio

9.20.4. Financial

9.20.5. Recent Industry Insights

9.20.6. SWOT Analysis

9.21. Diao Group Chengdu Pharmaceutical Co.,Ltd.

9.21.1. Company Basic Information and Sales Area

9.21.2. Main Business/Business Overview

9.21.3. Product Portfolio

9.21.4. Financial

9.21.5. Recent Industry Insights

9.21.6. SWOT Analysis

9.22. Shanghai SPH Xinyi Pharmaceutical Co.,Ltd.

9.22.1. Company Basic Information and Sales Area

9.22.2. Main Business/Business Overview

9.22.3. Product Portfolio

9.22.4. Financial

9.22.5. Recent Industry Insights

9.22.6. SWOT Analysis

9.23. Anhui Shengying Pharmaceutical Co.,Ltd.

9.23.1. Company Basic Information and Sales Area

9.23.2. Main Business/Business Overview

9.23.3. Product Portfolio

9.23.4. Financial

9.23.5. Recent Industry Insights

9.23.6. SWOT Analysis

9.24. Sichuan Tiande Pharmaceutical Co.,Ltd.

9.24.1. Company Basic Information and Sales Area

9.24.2. Main Business/Business Overview

9.24.3. Product Portfolio

9.24.4. Financial

9.24.5. Recent Industry Insights

9.24.6. SWOT Analysis

9.25. Hubei Ruihua Pharmaceutical Co.,Ltd.

9.25.1. Company Basic Information and Sales Area

9.25.2. Main Business/Business Overview

9.25.3. Product Portfolio

9.25.4. Financial

9.25.5. Recent Industry Insights

9.25.6. SWOT Analysis

9.26. Zhejiang Anbet Pharmaceutical Co.,Ltd.

9.26.1. Company Basic Information and Sales Area

9.26.2. Main Business/Business Overview

9.26.3. Product Portfolio

9.26.4. Financial

9.26.5. Recent Industry Insights

9.26.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Antinematode Drugs Market

Figure 4: Global Antinematode Drugs Market: Drivers

Figure 5: Global Antinematode Drugs Market: Challenges

Figure 6: Global Antinematode Drugs Market: Trends

Figure 7: Global Antinematode Drugs Market: Opportunity

Figure 8: Global Antinematode Drugs Market: Restraint

Figure 9: Global Antinematode Drugs Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Antinematode Drugs Market Value (USD Million) By Region

Figure 15: Global Antinematode Drugs Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Antinematode Drugs Market Value (USD Million) By Region

Figure 23: Global Antinematode Drugs Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

105 items

Table 1: Market Segmentation Analysis

Table 2: Global Antinematode Drugs Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Antinematode Drugs Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Antinematode Drugs Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Antinematode Drugs Market Value (USD Million) By Region

Table 10: Global Antinematode Drugs Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Antinematode Drugs Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Antinematode Drugs Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Antinematode Drugs Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: GlaxoSmithKline Basic Information And Sales Area

Table 31: GlaxoSmithKline. Products Portfolio

Table 32: Sequent Scientific Basic Information And Sales Area

Table 33: Sequent Scientific. Products Portfolio

Table 34: K.A. Malle Pharmaceuticals Basic Information And Sales Area

Table 35: K.A. Malle Pharmaceuticals. Products Portfolio

Table 36: Lasa Supergenerics Limited Basic Information And Sales Area

Table 37: Lasa Supergenerics Limited. Products Portfolio

Table 38: Fredun Pharmaceuticals Ltd Basic Information And Sales Area

Table 39: Fredun Pharmaceuticals Ltd. Products Portfolio

Table 40: Salius Pharma Basic Information And Sales Area

Table 41: Salius Pharma. Products Portfolio

Table 42: Johnson & Johnson Basic Information And Sales Area

Table 43: Johnson & Johnson. Products Portfolio

Table 44: Amneal Pharmaceuticals Basic Information And Sales Area

Table 45: Amneal Pharmaceuticals. Products Portfolio

Table 46: Cadila Pharmaceuticals Basic Information And Sales Area

Table 47: Cadila Pharmaceuticals. Products Portfolio

Table 48: Eipico Basic Information And Sales Area

Table 49: Eipico. Products Portfolio

Table 50: Esteve Pharmaceuticals Basic Information And Sales Area

Table 51: Esteve Pharmaceuticals. Products Portfolio

Table 52: Shanghai Tengrui Pharmaceutical Co.,Ltd. Basic Information And Sales Area

Table 53: Shanghai Tengrui Pharmaceutical Co.,Ltd.. Products Portfolio

Table 54: Shaanxi Hanwang Pharmaceutical Co.,Ltd. Basic Information And Sales Area

Table 55: Shaanxi Hanwang Pharmaceutical Co.,Ltd.. Products Portfolio

Table 56: Beijing Taiyang Pharmaceutical Co.,Ltd. Basic Information And Sales Area

Table 57: Beijing Taiyang Pharmaceutical Co.,Ltd.. Products Portfolio

Table 58: Guilin Nanyao Pharmaceutical Co.,Ltd. Basic Information And Sales Area

Table 59: Guilin Nanyao Pharmaceutical Co.,Ltd.. Products Portfolio

Table 60: Fujian Dongrui Pharmaceutical Co.,Ltd. Basic Information And Sales Area

Table 61: Fujian Dongrui Pharmaceutical Co.,Ltd.. Products Portfolio

Table 62: Jiaozuo Furuitang Pharmaceutical Co.,Ltd. Basic Information And Sales Area

Table 63: Jiaozuo Furuitang Pharmaceutical Co.,Ltd.. Products Portfolio

Table 64: Shaoxing Minsheng Pharmaceutical Co.,Ltd. Basic Information And Sales Area

Table 65: Shaoxing Minsheng Pharmaceutical Co.,Ltd.. Products Portfolio

Table 66: Chengdu Hengda Pharmaceutical Co.,Ltd. Basic Information And Sales Area

Table 67: Chengdu Hengda Pharmaceutical Co.,Ltd.. Products Portfolio

Table 68: China Resources Sanjiu (Beijing) Pharmaceutical Co.,Ltd. Basic Information And Sales Area

Table 69: China Resources Sanjiu (Beijing) Pharmaceutical Co.,Ltd.. Products Portfolio

Table 70: Diao Group Chengdu Pharmaceutical Co.,Ltd. Basic Information And Sales Area

Table 71: Diao Group Chengdu Pharmaceutical Co.,Ltd.. Products Portfolio

Table 72: Shanghai SPH Xinyi Pharmaceutical Co.,Ltd. Basic Information And Sales Area

Table 73: Shanghai SPH Xinyi Pharmaceutical Co.,Ltd.. Products Portfolio

Table 74: Anhui Shengying Pharmaceutical Co.,Ltd. Basic Information And Sales Area

Table 75: Anhui Shengying Pharmaceutical Co.,Ltd.. Products Portfolio

Table 76: Sichuan Tiande Pharmaceutical Co.,Ltd. Basic Information And Sales Area

Table 77: Sichuan Tiande Pharmaceutical Co.,Ltd.. Products Portfolio

Table 78: Hubei Ruihua Pharmaceutical Co.,Ltd. Basic Information And Sales Area

Table 79: Hubei Ruihua Pharmaceutical Co.,Ltd.. Products Portfolio

Table 80: Zhejiang Anbet Pharmaceutical Co.,Ltd. Basic Information And Sales Area

Table 81: Zhejiang Anbet Pharmaceutical Co.,Ltd.. Products Portfolio

Table 82: Global Market Value (USD Million) (2025-2032) By Application

Table 83: Global Market Share (%) By Application (2032)

Table 84: Global Market Value (USD Million) (2025-2032) By Types

Table 85: Global Market Share (%) By Types (2032)

Table 86: Global Antinematode Drugs Market Value (USD Million) By Region

Table 87: Global Antinematode Drugs Market Share (%) By Region (2025-2032)

Table 88: North America Market Value (USD Million) (2025-2032) By Country

Table 89: North America Market Value (USD Million) (2025-2032) By Application

Table 90: North America Market Value (USD Million) (2025-2032) By Types

Table 91: Europe Market Value (USD Million) (2025-2032) By Country

Table 92: Europe Market Value (USD Million) (2025-2032) By Application

Table 93: Europe Market Value (USD Million) (2025-2032) By Types

Table 94: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 95: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 96: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 97: South America Market Value (USD Million) (2025-2032) By Country

Table 98: South America Market Value (USD Million) (2025-2032) By Application

Table 99: South America Market Value (USD Million) (2025-2032) By Types

Table 100: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 101: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 102: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 103: Research Programs/Design For This Report

Table 104: Key Data Information From Secondary Sources

Table 105: Key Data Information From Primary Sources

FAQs

1. What is the Antinematode Drugs market size and its recent valuation?

The Antinematode Drugs market size was estimated at USD 1.15 billion in 2023, reflecting steady demand across human and veterinary segments. This valuation incorporates sales of broad-spectrum agents and niche formulations, positioning the market as a critical component of global antiparasitic therapy.

2. How is the market expected to grow through the forecast period?

The market is projected to expand at a compound annual growth rate of 5.8 % from 2024 to 2032, reaching roughly USD 1.9 billion by the end of the period. Growth is underpinned by rising infection rates and expanding veterinary applications.

3. Which factors are driving the expansion of the Antinematode Drugs market?

Key drivers include increasing prevalence of helminthic infections in emerging economies, heightened awareness of zoonotic transmission, growth in livestock production, and strong pipeline activity for novel oral and injectable agents. Health‑policy initiatives supporting deworming programs further amplify demand.

4. What are the primary challenges limiting market growth?

The market faces challenges such as emerging drug resistance, stringent regulatory approval pathways, limited reimbursement in low‑income regions, and high R&D costs for new compounds. Additionally, competition from generic antiparasitics pressures pricing and margins for innovators.

5. Which regions currently lead in sales and why?

North America currently leads in revenue, driven by advanced healthcare infrastructure and robust veterinary sectors. Europe follows, benefiting from stringent animal health regulations. Asia‑Pacific shows the fastest growth, propelled by expanding livestock populations and government deworming campaigns.

6. Who are the top companies competing in this space?

Leading players include Merck & Co., Bayer AG, Zoetis Inc., Novartis AG, and GSK. These firms dominate through extensive product portfolios, strategic acquisitions, and strong distribution networks across human and animal health channels. They also invest heavily in pipeline development targeting resistant nematode strains, reinforcing market leadership.

7. What future opportunities are emerging for market participants?

Future opportunities arise from personalized deworming regimens, biologic antiparasitic agents, and expansion into emerging markets with unmet veterinary needs. Digital health platforms for compliance monitoring and partnerships with agritech firms also open new revenue streams.

8. How are emerging technologies influencing product development?

Advanced drug‑delivery technologies, such as nano‑formulations and sustained‑release injectables, improve efficacy and reduce dosing frequency. AI‑driven target identification accelerates discovery of novel compounds, while genomics enables resistance‑monitoring tools that shape formulation strategies. These innovations collectively shorten time‑to‑market and enhance patient adherence, strengthening the market’s competitive edge.

9. What regulatory trends are shaping the market's future outlook?

Regulatory bodies worldwide are tightening guidelines on residue limits and safety testing for both human and animal anthelmintics. The future outlook depends on harmonized approval pathways, accelerated conditional licensing for breakthrough drugs, and clear policies supporting sustainable deworming programs.

Contact for Full Report

Loading report content...

Which Companies Lead the Antinematode Drugs Market in 2026?

Market Snapshot

Antinematode Drugs Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Antinematode Drugs Segmentation

Antinematode Drugs Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the Antinematode Drugs market size and its recent valuation?

2. How is the market expected to grow through the forecast period?

3. Which factors are driving the expansion of the Antinematode Drugs market?

4. What are the primary challenges limiting market growth?

5. Which regions currently lead in sales and why?

6. Who are the top companies competing in this space?

7. What future opportunities are emerging for market participants?

8. How are emerging technologies influencing product development?

9. What regulatory trends are shaping the market's future outlook?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Antinematode Drugs Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Antinematode Drugs Segmentation

Antinematode Drugs Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the Antinematode Drugs market size and its recent valuation?

2. How is the market expected to grow through the forecast period?

3. Which factors are driving the expansion of the Antinematode Drugs market?

4. What are the primary challenges limiting market growth?

5. Which regions currently lead in sales and why?

6. Who are the top companies competing in this space?

7. What future opportunities are emerging for market participants?

8. How are emerging technologies influencing product development?

9. What regulatory trends are shaping the market's future outlook?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation